Save Product
Product Details
Synonyms
PCSK9, FH3, HCHOLA3, LDLCQ1, NARC1, PC9
Source
Human PCSK9 (D374Y), His Tag (PCY-H5225) is expressed from human 293 cells (HEK293). It contains AA Gln 31 - Gln 692 (Accession # Q8NBP7-1 (D374Y)).
Predicted N-terminus: Gln 31
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus. This protein undergoes autocatalytic cleavage to release the pro-peptide and mature chain. The pro-peptide and mature chain are associated through non‑covalent interactions and with a calculated MW of 13.8 kDa and 58.2 kDa respectively. The protein migrates as 15 kDa and 55-65 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation. The D374Y mutation results in higher affinity of PCSK9 for LDLR.
Endotoxin
Less than 0.01 EU per μg by the LAL method / rFC method.
Purity
>90% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Human PCSK9 (D374Y), His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
SEC-MALS
The purity of Human PCSK9 (D374Y), His Tag (Cat. No. PCY-H5225) is more than 95% and the molecular weight of this protein is around 55-80 kDa verified by SEC-MALS.
Report
Bioactivity-ELISA
Immobilized Human LDL R, Fc Tag at 2 μg/mL (100 μL/well) can bind Human PCSK9 (D374Y), His Tag (Cat. No. PCY-H5225) with a linear range of 20-78 ng/mL (QC tested).
Protocol
Immobilized Human PCSK9 (D374Y), His Tag (Cat. No. PCY-H5225) at 1 μg/mL (100 μL/well) on Monoclonal Anti-His Tag Antibody, Mouse IgG1 (AY63) precoated (0.1 μg/well) plate can bind Evolocumab with a linear range of 0.1-4 ng/mL (Routinely tested).
Protocol
Bioactivity-SPR
Evolocumab (Cat. No. HY-P9930) captured on Protein A Chip can bind Human PCSK9 (D374Y), His Tag (Cat. No. PCY-H5225) with an affinity constant of 1.38 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Protocol
Bioactivity-BLI
Loaded Human LDL R, Fc Tag on Protein A Biosensor, can bind Human PCSK9 (D374Y), His Tag (Cat. No. PCY-H5225) with an affinity constant of 0.329 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Protocol
Bioactivity-FACS
FACS analysis shows that Human PCSK9 (D374Y), His Tag (Cat. No. PCY-H5225) inhibits LDL uptake in HepG2 cells. The EC50 for this effect is 0.0689-0.3049 μg/mL.
Protocol
FACS analysis shows that the effect of Human PCSK9 (D374Y), His Tag (Cat. No. PCY-H5225) inhibiting LDL uptake in HepG2 cells was neutralized by Anti-Human PCSK9 antibody. The concentration of PCSK9 used is 5 μg/mL. The EC50 for Anti-Human PCSK9 antibody is 6.816-12.67 μg/mL.
Protocol
Customer Reviews Writing Reviews
FAQ
- Product
What key experimental conditions should be considered for PCSK9–LDLR binding assays?
It is recommended to perform PCSK9–LDLR binding assays under acidic conditions, as the interaction exhibits higher activity in acidic environments compared to neutral ones. Reference: Effects of pH and Low Density Lipoprotein (LDL) on PCSK9-dependent LDL Receptor Regulation.
Background
Recent Advances
Drug Development Progress- English Name：
Proprotein convertase subtilisin kexin type 9
- Category：
- Approved Drugs：
8 Details
- Drugs in Clinical Trials：
35 Details
- Highest Development Stage：
Approved
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
